Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study

Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study

Objectives. Our aim was to evaluate the safety and efficacy of biodegradable polymer everolimus-eluting stents (BP-EES) compared with durable polymer everolimus-eluting stents (DP-EES) in midterm. Background. There are few data about midterm clinical outcomes of BP-EES compared with DP-EES. Methods...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hiroaki Matsuda, Ai Kagase, Takahiro Tokuda, Yusuke Ochiumi, Akira Murata, Yoriyasu Suzuki, Tatsuya Ito
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Journal of Interventional Cardiology
Online Access:	http://dx.doi.org/10.1155/2020/2869303
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Stent Fracture after Everolimus-Eluting Stent Implantation
by: Ali S. Almasood, et al.
Published: (2011-01-01)

Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model
by: Daisuke Kitano, et al.
Published: (2025-03-01)

Everolimus-Eluting Biodegradable Abluminal Coating Stent versus Durable Conformal Coating Stent: Termination of the Inflammatory Response Associated with Neointimal Healing in a Porcine Coronary Model
by: Masayuki Mori, et al.
Published: (2020-01-01)

Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis
by: Tingting Wei, et al.
Published: (2022-06-01)

Clinical Outcomes from Unselected “Real-World” Patients with Long Coronary Lesion Receiving 40 mm Biodegradable Polymer Coated Sirolimus-Eluting Stent
by: Anurag Polavarapu, et al.
Published: (2015-01-01)

Patient Safety Events Related to the Placement of Drug-Eluting Stents
by: Patient Safety Authority
Published: (2023-12-01)

Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents
by: Piotr Rola, et al.
Published: (2021-01-01)

Effect of rapamycin-eluting stents on in-stent restenosis and early inflammatory response in coronary artery narrowing animal models
by: Jianbing Zhang, et al.
Published: (2025-01-01)

Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
by: Robert J. Gil, et al.
Published: (2020-01-01)

Impact of Obstructive Sleep Apnea on In-Stent Restenosis in Coronary Heart Disease Patients after Elective Drug-Eluting Stenting
by: Wenjie Yang, et al.
Published: (2025-01-01)

Everolimus in Heart Transplantation: An Update
by: Stephan W. Hirt, et al.
Published: (2013-01-01)

Polymers for Cardiovascular Stent Coatings
by: Anne Strohbach, et al.
Published: (2015-01-01)

Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents
by: Amir F. Mohani, et al.
Published: (2018-01-01)

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR
by: Zhongxia Wang, et al.
Published: (2016-01-01)

Efficacy and Safety of Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents for Chronic Total Occlusions: Insights from the Coroflex ISAR 2000 Worldwide Registry
by: Ahmad Syadi Mahmood Zuhdi, et al.
Published: (2018-01-01)

Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials
by: Alfredo E. Rodriguez, et al.
Published: (2024-07-01)

Corrigendum to “Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR”
by: Zhongxia Wang, et al.
Published: (2019-01-01)

Modelling chemistry and biology after implantation of a drug-eluting stent. Part Ⅱ: Cell proliferation
by: Adam Peddle, et al.
Published: (2018-09-01)

Modelling chemistry and biology after implantation of a drug-eluting stent. Part Ⅰ: Drug transport
by: Tuoi Vo, et al.
Published: (2017-03-01)

Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage
by: Paul Gonzales, et al.
Published: (2017-01-01)

A comparison of drug‐eluting stent and coronary artery bypass grafting in mildly to moderately ischemic heart failure
by: Kun Wang, et al.
Published: (2022-06-01)

Catlet scoring system as a new predictor for in-stent restenosis in patients with chronic coronary artery disease undergoing percutaneous coronary intervention with drug-eluting stent
by: Juan Wang, et al.
Published: (2025-01-01)

Everolimus for Compassionate Use in Multiple Basal Cell Carcinomas
by: Laura Eibenschutz, et al.
Published: (2013-01-01)

Drug-Coated versus Uncoated Balloon for Side Branch Protection in Coronary Bifurcation Lesions Treated with Provisional Stenting Using Drug-Eluting Stents: A Meta-analysis
by: Zhi-Ming Jiang, et al.
Published: (2022-01-01)

Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
by: Nicolas W. Shammas, et al.
Published: (2013-01-01)

Incidence and Predictors of Outcome in the Treatment of In-Stent Restenosis with Drug-Eluting Balloons, a Real-Life Single-Centre Study
by: Kyle Murnaghan, et al.
Published: (2022-01-01)

Peripheral Artery Disease Intervention: Drug-Coated Balloon vs Drug-Eluting Stent, A Long-Term Comparison
by: Nathan Marzlin, et al.
Published: (2022-01-01)

Low Resolution Limits and Inaccurate Algorithms Decrease Significantly the Value of Late Loss in Current Drug-Eluting Stent Trials
by: Johannes B. Dahm, et al.
Published: (2012-01-01)

Prognostic Value of Plasma Pentraxin-3 Levels in Patients with Stable Coronary Artery Disease after Drug-Eluting Stent Implantation
by: Liu Haibo, et al.
Published: (2014-01-01)

Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry
by: You-Jeong Ki, et al.
Published: (2020-01-01)

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
by: Chun Shing Kwok, et al.
Published: (2014-01-01)

Efficacy and safety of everolimus for patients with focal cortical dysplasia type 2
by: Se Hee Kim, et al.
Published: (2025-02-01)

Biodegradable Polymers and Textiles
by: Sandra Varnaitė-Žuravliova, et al.
Published: (2025-01-01)

Combination of the endoscopic septonasal flap technique and bioabsorbable steroid-eluting stents for repair of congenital choanal atresia in neonates and infants: a retrospective study
by: Peng-peng Wang, et al.
Published: (2021-08-01)

Comparison of First- and Second-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes Based on the Hemoglobin A1c Level
by: Yong Hoon Kim, et al.
Published: (2020-01-01)

Correction to: Combination of the endoscopic septonasal flap technique and bioabsorbable steroid-eluting stents for repair of congenital choanal atresia in neonates and infants: a retrospective study
by: Peng-peng Wang, et al.
Published: (2021-11-01)

Biodegradable Polymers for Microencapsulation Systems
by: Joana Filipa Parente, et al.
Published: (2022-01-01)

Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient
by: Serena Patel, et al.
Published: (2018-01-01)

Structural Design of Mechanical Property for Biodegradable Polymeric Stent
by: Yunbo Wei, et al.
Published: (2019-01-01)

Effect of high-quality nursing interventions on the quality of life and cardiac index in acute coronary syndrome patients treated with drug-eluting stents: a randomized trial study
by: Zeinab Abdollahifar, et al.
Published: (2025-01-01)